Table 5 Adverse event rates during treatment with ANA and CANA
CANA | ANA | |
|---|---|---|
sJIA | sJIA | |
(n = 26 patients, PY = 56.4) | (n = 80 patients, PY = 228) | |
Events; Rate per 100 PY (95% CI) | Events; Rate per 100 PY (95% CI) | |
AE total | 15; 26.6 (14.9; 43.9) | 45; 19.7 (14.4; 26.4) |
Infections | 6; 10.6 (3.9; 23.2) | 15; 6.6 (3.7; 10.9) |
Headache | 5; 8.9 (2.9; 20.7) | 8; 3.5 (1.5; 6.9) |
Neutropenia | 3; 5.3 (1.1; 15.5) | 9; 3.9 (1.8; 7.5) |
Increase of transaminases | 6; 10.6 (3.9; 23.2) | 11; 4.8 (2.4; 8.6) |
Urticaria | 2; 0.9 (0.1; 3.2) | |
Hematuria | 4; 1.8 (0.5; 4.5) | |
Skin reaction | 2; 0.9 (0.1; 3.2) | |
Proteinuria | 2; 3.5 (0.4; 12.8) | 4; 1.8 (0.5; 4.5) |
Dizziness | ||
Local site reaction/ aversion | 1; 1.8 (0.0; 9.9) | 5; 2.2 (0.7; 5.1) |
Nausea | 1; 0.4 (0.0; 2.4) | |
Leucopenia | 1; 0.4 (0.0; 2.4) | |
Thrombocytopenia | 1; 1.8 (0.0; 9.9) | |
Stomach pain | 1; 1.8 (0.0; 9.9) | |
Breast pain | 1; 1.8 (0.0; 9.9) | |
Nocturnal sweating | 1; 0.4 (0.0; 2.4) | |
Acne | 3; 1.3 (0.3; 3.8) |